The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...

Carey said the take-home message is “if you have a patient who’s had MS and optic neuritis, and they call your office saying, ...

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision. Fovlussea enters a European market where ranibizumab biosimilars have been commercially ...

Patients who say their eyes feel dry, gritty, or burning are among the most common in ophthalmology, and treating them well ...

The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...

Prevent Blindness is observing its sixth annual Inflammatory Eye Disease (IED) Week from October 19 to 25, 2026, highlighting conjunctivitis and keratitis, thyroid eye disease (TED), and uveitis. 1 ...

LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...

The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...

The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...

David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.